Page last updated: 2024-10-19

niacinamide and Desmoid

niacinamide has been researched along with Desmoid in 4 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Research Excerpts

ExcerptRelevanceReference
"A recent randomized trial demonstrated that sorafenib improved progression free survival (PFS) in patients with desmoid tumors despite many patients experiencing stable disease or spontaneous regression without treatment."9.69A cost analysis of sorafenib for desmoid tumors. ( Ford, CN; Johns, MS; Lee, WM; Merritt, WT; Petrelli, NJ; Rhodes, L; Sheldon, Y; Thompson, M; Tiesi, GJ, 2023)
"Sorafenib is currently one of the recommended treatments for symptomatic patients with desmoid-type fibromatosis (DTF)."8.31Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose. ( Barwad, A; Dhamija, E; Gamangatti, S; Gangadharaiah, BB; Garg, V; Rastogi, S; Upadhyay, A, 2023)
"After Institutional Review Board (IRB) approval, we reviewed data for 26 patients with desmoid tumors treated with sorafenib."7.77Activity of Sorafenib against desmoid tumor/deep fibromatosis. ( Ahn, L; Antonescu, CR; D'Adamo, DR; Gounder, MM; Hameed, M; Keohan, ML; Lefkowitz, RA; Maki, RG; Singer, S; Stout, K, 2011)
"A recent randomized trial demonstrated that sorafenib improved progression free survival (PFS) in patients with desmoid tumors despite many patients experiencing stable disease or spontaneous regression without treatment."5.69A cost analysis of sorafenib for desmoid tumors. ( Ford, CN; Johns, MS; Lee, WM; Merritt, WT; Petrelli, NJ; Rhodes, L; Sheldon, Y; Thompson, M; Tiesi, GJ, 2023)
"Sorafenib is currently one of the recommended treatments for symptomatic patients with desmoid-type fibromatosis (DTF)."4.31Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose. ( Barwad, A; Dhamija, E; Gamangatti, S; Gangadharaiah, BB; Garg, V; Rastogi, S; Upadhyay, A, 2023)
"After Institutional Review Board (IRB) approval, we reviewed data for 26 patients with desmoid tumors treated with sorafenib."3.77Activity of Sorafenib against desmoid tumor/deep fibromatosis. ( Ahn, L; Antonescu, CR; D'Adamo, DR; Gounder, MM; Hameed, M; Keohan, ML; Lefkowitz, RA; Maki, RG; Singer, S; Stout, K, 2011)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's2 (50.00)2.80

Authors

AuthorsStudies
Johns, MS1
Merritt, WT1
Rhodes, L1
Ford, CN1
Thompson, M1
Lee, WM1
Sheldon, Y1
Petrelli, NJ1
Tiesi, GJ1
Garg, V1
Gangadharaiah, BB1
Rastogi, S1
Upadhyay, A1
Barwad, A1
Dhamija, E1
Gamangatti, S1
Benech, N1
Walter, T1
Saurin, JC1
Gounder, MM1
Lefkowitz, RA1
Keohan, ML1
D'Adamo, DR1
Hameed, M1
Antonescu, CR1
Singer, S1
Stout, K1
Ahn, L1
Maki, RG1

Trials

1 trial available for niacinamide and Desmoid

ArticleYear
A cost analysis of sorafenib for desmoid tumors.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:3

    Topics: Aged; Costs and Cost Analysis; Fibromatosis, Aggressive; Humans; Medicare; Niacinamide; Phenylurea C

2023

Other Studies

3 other studies available for niacinamide and Desmoid

ArticleYear
Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 186

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Drug-Related Side Effec

2023
Desmoid Tumors and Celecoxib with Sorafenib.
    The New England journal of medicine, 2017, 06-29, Volume: 376, Issue:26

    Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Female

2017
Activity of Sorafenib against desmoid tumor/deep fibromatosis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jun-15, Volume: 17, Issue:12

    Topics: Adolescent; Adult; Benzenesulfonates; Female; Fibromatosis, Aggressive; Humans; Magnetic Resonance I

2011